AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CAB
Description: CAB 30 mg tablets
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral CAB
Description: CAB 30 mg tablets
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV-LA Loading Dose
Description: 900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV-LA Loading Dose
Description: 900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB-LA Loading Dose
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB-LA Loading Dose
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV-LA Maintenance Dose
Description: 600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV-LA Maintenance Dose
Description: 600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB-LA Maintenance Dose
Description: 400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
Study NCT04317105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02426983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Current Stimulation
Description: Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks.
Study NCT02426983 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct Current Stimulation
Description: Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks.
Study NCT02426983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
Study NCT02426983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
Study NCT02963727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly derived mesenchymal stem cell
Description: Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
Study NCT03919890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7684
Description: Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
Study NCT03919890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7684 Placebo
Description: Placebo comparator
Study NCT00619684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT01173627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test fentanyl citrate 400 mcg troche
Description: Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
Study NCT01173627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actiq 400 mcg
Description: Actiq 400 mcg administered as a single dose under fasted conditions
Study NCT03158649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embarazo y Bienestar
Description: The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page.
Study NCT03679208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device coded KIO014
Description: Innovative chitosan-based biomaterial intended for intraarticular injection.
Study NCT04317105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03464552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: oral capsule 3 hours before procedure
Study NCT03464552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopic guided biopsy
Description: Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
Study NCT04317105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03679208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane(r) as control device
Description: Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
Study NCT04120792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous exercise and cognitive training
Description: Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
Study NCT04120792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
Study NCT04120792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
Study NCT04120792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral video
Description: Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
Study NCT02030561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + NK cells
Study NCT04317105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT04228172 — intervention group
Intervention type: GENETIC
Intervention: DNA/GeneticTesting
Description: Subjects will be tested for GBA and LRRK2 mutation status at baseline.
Study NCT04228172 — intervention group
Intervention type: RADIATION
Intervention: FDG PET scan
Description: 18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.
Study NCT04228172 — intervention group
Intervention type: OTHER
Intervention: MRI scan
Description: Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB-LA Maintenance Dose
Description: 400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
Study NCT02451293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (N-acetyl-5-methoxytryptamine)
Study NCT02451293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04035759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APPEAL
Description: Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
Study NCT04228172 — intervention group
Intervention type: OTHER
Intervention: Clinical and neuropsychological assessments
Description: Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
Study NCT02069262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rebleeding
Description: Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
Study NCT02069262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rebleeding
Description: Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
Study NCT04590339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided inferior Alveolar Nerve lateralization
Description: Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
Study NCT01833754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered as three 70 mg/mL prefilled syringe injections
Study NCT03086421 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
Study NCT01250288 — intervention group
Intervention type: OTHER
Intervention: Personal Health Management System
Description: BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
Study NCT02294773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
Study NCT02294773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Patient is to take clomiphene citrate during cycle days 3-7.
Study NCT02294773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Patient is to take letrozole during cycle days 3-7.
Study NCT02723877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR309
Description: Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
Study NCT02723877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: non.taxane microtubule dynamics inhibitor
Study NCT03464552 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colposcopic guided biopsy
Description: Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
Study NCT01865084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally
Study NCT01865084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02857361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual ketamine wafers
Description: Two sublingual ketamine 25 mg wafers
Study NCT03887403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention
Study NCT03464552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: oral capsule 3 hours before procedure
Study NCT03887403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT03887403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT00953550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium-Sugammadex
Description: Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
Study NCT00953550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: 1 mg/kg
Study NCT00376740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Study NCT03990766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline delivered via high-volume, low-pressure nasal saline irrigation
Study NCT00096954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab (Xolair)
Description: Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of > 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
Study NCT00096954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
Study NCT04274478 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Auditive cueing
Description: Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
Study NCT03990766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal
Description: Lactose delivered via high-volume, low-pressure nasal saline irrigation
Study NCT02060201 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Study NCT06332248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).
Study NCT06332248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, oral intake once a day for up to three months.
Study NCT00964132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX194204
Description: Once Daily, Oral
Study NCT01607268 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy Imaging
Description: Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
Study NCT03973073 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CapulinTM
Description: camouflage
Study NCT03973073 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: topical applications and NB-UVB
Description: combination therapy of vitiligo
Study NCT00126113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPT-based Counseling
Description: Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
Study NCT00126113 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Educational Counseling
Description: Standard educational counseling consisting of explanation of hearing tests
Study NCT02060201 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Study NCT02060201 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin/Dapagliflozin FDC
Study NCT02949765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sulfate 105 mg
Description: Daily supplementation with iron sulfate 105 mg 1 pill/day
Study NCT02949765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-rich diet
Study NCT02464787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LifePak Nano
Description: Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
Study NCT01452776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
Study NCT00376740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Study NCT00499824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education of general practitioners on the IDF-WPR guidelines
Description: The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient.